Comportamiento metabólico de la proteína S100B como posible biomarcador diagnóstico en pacientes con riesgo de asfixia perinatal: un estudio descriptivo
Thesis
Introduction: Perinatal asphyxia (PA) causes significant neonatal morbidity and mortality worldwide. Currently, there is no parameter to measure the neurological damage after a PA event in its early phase. Although the neuronal protein S100B has high potential to achieve this goal, research to date has been inconclusive. Objective: Determine whether the measurement of S100B in peripheral blood serum, at 12 and 48 hours after birth, is a useful biomarker in the diagnosis of patients at risk of PA. Methodology: A cross-sectional study was carried out in a high complexity hospital in Bogotá between June 2017 and July 2018. Patients who met at least one of the inclusion criteria for PA according to ACOG (n=23) were included. Serum quantification of S100B was performed to all of them. Possible statistical associations between clinical variables and protein metabolic behavior were explored. Results: The average protein measurement at 12 hours (23.85) was slightly higher than at 48 hours (16.11); however, there was no statistically significant difference between both times. There was a variable dependence between protein at 48 hours and gender of the newborn. (p<0,05). Conclusions: Serum levels of S100B can be used as a diagnostic biomarker of PA; however, other research studies with larger sample sizes are required to validate the results obtained.
